NCT05923190 2026-03-19
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
Fox Chase Cancer Center
Phase 2 Active not recruiting
Clinical Trials
4 trialsNCT04963153 2026-03-18
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06483334 2026-02-18
MK-3475-04C
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT04754191 2026-02-12
ENCORE
University of Utah
Phase 2 Active not recruiting